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Abstract
Hepatitis A remains a significant problem in travelers to developing nations.
Immune serum immunoglobulin (ISIG), administered intramuscularly, is an
effective form of prophylaxis but must be given every 5-6 months for
extended stay or repeat travelers. Although the prevalence of immunity to
hepatitis A in developed nations is relatively low, certain subgroups of the
travel population may have a high enough prevalence of immunity to render
screening a reasonable alternative to routine ISIG prophylaxis. Previous
studies of British travelers have indicated that older patients, those of Asian
descent, and those with a history of jaundice, may fulfill such criteria. Such
criteria in U.S. travelers have not been studied.
A retrospective study of patients at two U.S. university-affiliated travel
clinics was performed to assess the value of certain indicators in past
medical and travel history to predict immunity to hepatitis A. 762 patients
above the age of 16 seen in either clinic were tested for hepatitis A antibody
during 1987-1990. 112 immune subjects (15%) were identified. 61 immune
individuals aged 18 to 81 and 121 non-immune individuals, aged 17-71,
were studied. Of the 61 immune subjects, 48(79%) were over the age of 40,
whereas 50(41%) of the non-immune subjects were over the age of 40
(pc.0005) (odds ratio 5.2, 2.7-10.2, 95% Cl). Twenty-two (36%) of the
immune individuals were bom outside of the U.S., whereas 14 (12%)

of the

non-immune individuals were born outside of the U.S. (pc.0005)(odds ratio
4.3, 2.1-8.9, 95% Cl). Nineteen (31%) of the immune individuals gave a
history of hepatitis whereas two (2%) of the non-immune individuals gave
such a history (pc.0005)(odds ratio 26.2, 9.0-80.3, 95% Cl). Fifty-three
(87%) of immune individuals gave a history of previous travel to developing
nations whereas 75 (62%) of non-immune individuals gave such a history
(pc.001)(odds ratio 4.1, 1.9-9.0, 95% Cl). Screening for immunity may be an
appropriate alternative to routine ISIG prophylaxis in extended stay or
repeat U.S. travelers if they are >40 years old, were born outside of the U.S.,
or give a history of hepatitis or of travel to developing nations.
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Introduction
Hepatitis A is a significant complication of travel to the developing
nations. A lower prevalence of immunity in the developed nations,
combined with a higher incidence of disease and poorer sanitation
measures in the developing nations renders unprotected travelers
susceptible to contracting hepatitis A. Current Centers for Disease
Control (CDC) recommendations call for passive immunization with
pooled serum immunoglobulins(ISIG), which is an effective means of
prophylaxis for these travelers. However, ISIG prophylaxis must be
repeated every four to six months and is unnecessary and inconvenient
for patients who have already developed a natural, active and lifelong
immunity. Several studies performed in England have suggested that
certain subpopulations of travelers to developing nations have a high
enough prior probability of immunity to render serological testing a costeffective screen. The purpose of this study was to search for factors in the
past medical and travel history of patients at American travel clinics
which might be associated with immunity. Determination of such factors
might allow the clinician to use the patient interview to identify patients
with a greater chance of immunity than that of the general population.
Although this study is not designed to quantitatively assess the costeffectiveness of serological testing in these patients, it provides the
clinician with qualitative information that may enable him or her to spare
the patient unnecessary ISIG injections.

6

In this introduction, the clinical importance of hepatitis A will first be
reviewed, followed by a description of the risks posed to the U.S. travel
clinic patient of contracting the disease. These risks are not wellquantified, and few studies even attempt to measure their magnitude.
The effectiveness and safety of ISIG prophylaxis will then be addressed,
as well as the importance of other considerations regarding its use.
Finally, studies in England considering the prevalence of hepatitis A
immunity in travel clinics and the costs of screening and prophylaxis will
be reviewed, for their significance in the design of this study.
Clinical Importance of Hepatitis A
Epidemiology in General Population
Hepatitis A is one of the less morbid hepatitides but is still of
considerable clinical significance. 21,532 cases were reported to the CDC
in 1983 and of the 7854 serologically confirmed cases, 33.2% were
hospitalized and 0.6% died. In comparison, 1.6% of 8925 serologically
confirmed cases of hepatitis B (24318 cases in total) ended in death and
44.4% were hospitalized. 6.1% of the cases of hepatitis A reported in that
year were attributed to international travel (1).
Etiology
The disease is caused by a 27 nanometer nonenveloped RNA
picomavirus which is quite resistant to inactivation by physical and
chemical means (2). Although the natural means of transmission of the
virus is considered to be fecal-oral, parenteral inoculation is a successful
method of inducing infection in experimental animals and in test
subjects. Within one to two weeks after inoculation by either route, virus
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is present in the liver, serum and stool (3). Fecal excretion and viremia
generally disappear within days of the arrival of symptoms, at about four
weeks after inoculation (4,5). Jaundice and elevations of alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) appear at
about this time, as well as anti-hepatitis A virus (HAV) IgM, as
determined by enzyme-linked immunosorbent assay (ELISA)(6). The
jaundice, elevated transaminases and symptoms are usually completely
resolved by approximately three months after inoculation, whereas antiHAV IgM persists in up to 30% of subjects (93% in one study) at six
months after inoculation(7,8,9). Anti-HAV IgG appears at about four
weeks after inoculation and probably persists for life, conferring active
immunity on the subject(lO).
Clinical Presentation
The spectrum of presentation is quite varied. Fulminant hepatitis A is
rare and is associated with jaundice, dark urine, abdominal pain and
nausea(ll). As the prevalence of immunity in adult populations is much
higher than the number of positive histories of jaundice or hepatitis
would suggest, a large number of cases of hepatitis A must be
asymptomatic. Hadler(12) found a rate of 84%, 50% and 20% of
asymptomatic infections for day-care children aged 2, 3 to 4 and over 5
years, respectively, while 11% of inoculated adult volunteers were found
to be asymptomatic(13). A recent Chinese study of preschool children
subjected to a common-source exposure to hepatitis A found that 25% of
the children had an inapparent infection documented only by the
presence of anti-HAV IgM or a change in anti-HAV IgG titers, while 50%
of the children demonstrated a change in ALT and another 25% of the
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children had clinical symptoms and jaundice. All children were found to
be excreting HAV in their stools(14).

Thus, both extremes of expression

of hepatitis A are clinically significant for travelers. Hepatitis A can cause
death, as well as cause a large number of asymptomatic infections.
Furthermore, it is clear that a significant proportion of infected
individuals may produce infectious stools without any overt signs of
disease.
Attempts to Assess and Control Risk to Unprophvlaxed U.S.
Travelers of Contracting Hepatitis A During Travel to
Developing Nations
The risk of travelers from the developed countries contracting
hepatitis A during travel to the developing nations depends on several
factors, most of which have been poorly quantified.

First, the prevalence

of immunity among the travelers themselves must be considered, along
with the incidence of infection in a given region of travel. The
epidemiological pattern of infection in a given region, and putative
explanations for this pattern may be even more important than reported
incidences. The behavior of the travelers will determine the extent to
which they expose themselves to the risks of infection posed by the
environment and individuals in the region of travel. Finally, the efficiency
of immunoprophylaxis, if given, must be considered.
Prevalence of Immunitv/Susceptibilitv in the U.S.
In the United States, a wide range of prevalences of anti-HAV IgG has
been reported(15,16). Prevalence increases with increasing age and with
decreasing socioeconomic status. Thus, for example, less than 10% of
middle-class children tested in 1976 were HAV immune as compared to
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nearly 75% of middle-class adults over 50 years old. Among poor, black
populations in New York City, prevalence rose from 50% to over 75% in
subjects aged 20 to over 50 years. Other factors have been suggested as
playing a role as well. Foreign-bom individuals had an age-adjusted
prevalence of 75% in these studies, as compared with 31% in Americanborn individuals. Middle-class whites with serological evidence of
exposure to hepatitis B had a higher prevalence (54%) than those without
such evidence (31%). In these studies, homosexuals did not have a higher
prevalence. Furthermore, only 3-5% of HAV immune subjects gave a
history of hepatitis! 15,16).
These data suggest that, to the extent that a travel clinic population
represents a cross-section of American society, a significant fraction of a
travel clinic population would not be immune to hepatitis A, and would
therefore be susceptible to contracting the disease during travel to
developing nations. On the other hand, socioeconomic profiles of U.S.
travel clinic populations in general, or the populations in this study are
not available to confirm or refute the assumption that they represent a
cross-section of U.S. society. However, since international travel is costly
and since attendance at travel clinics usually requires self-payment by the
patient, the socioeconomic status of our travel clinic population is
probably higher than that of the general U.S. population. This would
suggest that even a greater proportion of these travelers would be nonimmune.
In any case, these data demonstrate that there is no group in which the
immune status of an individual could be a virtual certainty based on
membership in that group. Furthermore, these studies were completed

in the mid-1970's and prevalence among the younger age-groups might
be substantially lower now. Indeed, the incidence of symptomatic
hepatitis A is currently one case per 100,000 person-years, which would
suggest that the prevalence of immunity among younger age-groups is
now very low(17). Thus, in the absence of serological testing, the CDC
recommends routine ISIG prophylaxis for all travelers to developing
nations. How these prevalence data might render the serological testing
of certain subgroups a reasonable alternative to ISIG prophylaxis,
however, will be discussed later.
Incidence and Prevalence of Hepatitis A in Developing
Nations
The true incidence of infection in the developing nations is also
important in determining the risks for travelers of contracting hepatitis
A. The lack of a carrier state and the short period of fecal shedding
renders only currently infected individuals contagious either through
personal contact or through contamination of food or water supplies.
However, data on incidence is more difficult to collect than is data on
prevalence. Furthermore, because hepatitis A is often an asymptomatic
disease, reported incidence may give a misleading indication of how
many people might actually be shedding virus at any one time. For
example, a study in Israel demonstrated an increase in incidence of viral
hepatitis from 0.8 to 1.2 cases per 1000 in the years 1951-1985 during
which sanitary conditions had improved (18). An increase in the rate of
reporting might explain these findings or, as the authors suggest,
improved sanitary conditions may have caused the age of peak incidence
to increase from the 1-4 year old age group to the 5-9 year old age group.

when more infections are symptomatic. Thus, the number of people
shedding virus might have decreased despite the apparent increase in
incidence. A similar pattern was hypothesized for poliomyelitis following
the sanitary improvements of the 20th century. On the other hand, an
improvement in sanitary conditions of San Roma, Costa Rica was used to
explain the drop in incidence of viral hepatitis in that city, from 253 to
25 annual cases between the years 1973-1980(19). In neither of these
two studies is serological type reported, which further emphasizes the
difficulty in interpreting data such as these.
Seroprevalence in very young populations could also be used as an
indicator of the current, true incidence. A study of schoolchildren in
Naples, Italy showed a decline in prevalence of anti-HAV IgG from 20.0%
to 5.2% of seven-year olds between the years 1980 and 1988. These data
came from different, albeit socioeconomically similar, districts and the
change was attributed to improvement in sanitation(20). In contrast, in
several small villages in the Andes, a prevalence of 86.9% was seen even
in the 1-5 year-old age group, with no statistically significant differences
between age groups, leading one to believe that hepatitis A continues to
be hyperendemic in this region(21).
Patterns of Infection in Developing Nations
It is clear that quantitative assessments of infection rates in developing
countries are rare and difficult to interpret. Thus, immunoprophylaxis is
recommended for travel to all developing nations, and the classification
of nations as "developing" is left ot the judgment of the clinician. Some
greater discretion might be attained by classifying regions where

hepatitis A is present in hyperendemic, endemic and epidemic form. For
example, in the villages in the Andes, with a uniformly high prevalence
rate in young children, hepatitis A is hyperendemic, signifying that
exposure is universal by a very young age, presumably because sanitation
is poor enough to allow continual common-vehicle transmission. Because
of the young age at transmission, virtually all infections are asymptomatic.
Apparently, although these populations would be expected to be small
and isolated, the number of susceptibles is never exhausted. Otherwise,
periodic re-introduction of the virus, with resulting epidemics and
significant numbers of symptomatic cases would have to be postulated for
such a high prevalence. In hyperendemic regions, a traveler would have a
high risk of being exposed to HAV in drinking water, food and even
personal contact.
Endemic regions are those in which sanitation has improved enough so
that common-vehicle transmission becomes less important than personto-person transmission. Most cases are asymptomatic, which facilitates
spread, but first exposure may occur at later ages, and so some cases will
be symptomatic, giving rise to the appearance of small epidemics.
Indeed, regions in which hepatitis A is solely epidemic are those in
which there is a large susceptible population because of a low recent
incidence, which could be caused by minimal opportunities for commonvehicle or person-to-person transmission. Epidemiologic data from the
developed countries suggests that hepatitis A is primarily an epidemic
disease, and that continual, serial transmission or common-vehicle
transmission is prevented by public health surveillance. Because of the
difficulty of determining the incidence of asymptomatic infection, it is

difficult to classify regions where hepatitis A is endemic, however, many
nations which are steadily improving their sanitation systems are
probably passing through a phase of endemicity(47). Israel may be an
example of such a nation. Travelers to endemic regions are at risk of
exposure to HAV from personal contact with recently infected, albeit
asymptomatic individuals. However, as in epidemic regions, the traveler
is also at risk from large common-source outbreaks as occurs, for
example, when water supplies are contaminated during accidental
release of sewage during floods.
Again, although the clinician may try to classify regions as
hyperendemic, endemic and epidemic and apprise the patient of the
risks in each region, quantitative data that would allow for an accurate
determination of risk are not available. One might otherwise attempt to
quantify a traveler’s risk of contracting hepatitis A in terms of his or her
exposure to the vehicles of transmission. It is generally accepted that
hepatitis A is spread by the fecal-oral route and therefore, that infectious
fecal contamination of food or water or parts of the body that, unwashed,
will have contact with the mouth, is the means of spread.
Vehicles of Transmission
Contamination of the water-supply is a well-recognized cause of
epidemics, although waterborne outbreaks account for less than 1% of
the total number of reported cases of hepatitis A(24). Although the WHO
has recommended treating drinking water with a free chlorine residual
of 0.3-0.5 mg/Liter for 30 minutes and isolating no viruses per 100 to
1000 liters of drinking water, water with a free chlorine residual of 0.2-

0.8 mg/L that was then contaminated in the distribution system and
associated with a huge hepatitis A outbreak in India was found to have
other viruses in concentrations of 1-7 plaque-forming units per 12-40 L
of drinking water(24,25). Thus, even in regions where water is treated,
the traveler is at risk when sewage contamination of the water system
occurs, as sometimes occurs during monsoon flooding. Travelers are also
at risk where water is not treated or chlorinated. Aside from the risks of
obvious contamination with human waste, ponds and wells in Ghana and
China have been shown to contain Enterovirus even though there was no
known source. Contaminated water is also known to spread hepatitis A
when used to clean dishes or when used in aerosol irrigation. Finally,
recreational activites associated with contaminated lakewater have been
implicated in one outbreak of hepatitis A(26).
The traveler can reduce risk by not drinking or using potentially
contaminated water. Portable chemical additives such as sodium
hypochlorite (lOmg/L), iodine (3mg/L) and potassium permanganate
(30mg/L) have been found to inactivate hepatitis A in contaminated
drinking water. Boiling water will also kill the virus(2).
Another source of hepatitis A infection is foodborne virus. This is
generally associated with shellfish, which are often eaten uncooked and
which, in fecally contaminated water, can concentrate the virus to an
infectious level. Information about the risk in developing nations is
lacking; in the U.S., however, shellfish outbreaks accounted for less than
4% of cases in 1981(27). As the virus can withstand temperatures of
60' C for 60 minutes, even steaming shellfish is unlikely to

decontaminate it. Other food products, primarily uncooked, have been
associated, if rarely, with hepatitis A outbreaks(26).
Contaminated food-handlers are another possible source of infection.
Contaminated foodhandlers accounted for 7% of cases in the U.S. in
1981(27). Several states in the U.S. require restauraunt employees to
wash their hands before returning to work after using toilet facilities, but
it is difficult to quantitate the effect such behavior or lack thereof would
have on the international traveler. A recent study found no increased
incidence of hepatitis A in " adventure " travelers who lived in cheap
accomodations or camped, as opposed to travelers who stayed in
international level hotels, which may suggest a limited role for
foodhandler transmission as well as for use of untreated water(28).
Ordinary person-to-person contact is an unlikely mode of spread unless
one person is fecally incontinent or his or her hands

otherwise become

fecally contaminated. The only healthy people who are consistently
fecally incontinent are young children and thus, person-to-person contact
is a frequent mode of spread in the context of day-care center outbreaks.
Since some long-term travelers place their children in day-care centers,
these travelers are at risk of contracting hepatitis A from their young,
untoilet-trained children. The risk is especially pronounced since
children, as well as adults in endemic regions are very likely to have
asymptomatic infections. Homosexual sexual relations are considered to
be a form of person-to-person contact that abets the transmission of
hepatitis A. No such predilection has been demonstrated among
travelers, however. Likewise, parenteral modes of transmission have only
rarely been documented for hepatitis A and have not been reported in

travelers. Thus, no recommendations about personal contact with natives
that would substantially alter risk can be made.
It is clear from this discussion that quantifying a traveler's risk of
contracting hepatitis A based on exposure to the vehicles of transmission
is difficult. A clinician can warn a patient to avoid consuming water or
food that might be fecally contaminated, or to be wary of certain types of
personal contact, but specific quantitative data that would allow the
clinician to reject ISIG prophylaxis on the basis of expected forms of
exposure during travel do not exist.
Incidence of Hepatitis A in Travelers from Developed
Nations During Travel to Developing Nations
Although the importance of individual risks is difficult to quantitate,
there have been several studies that have been able to provide some
information on the incidence of hepatitis A in travelers from the
developed nations. A preliminary study of American travelers in 1972
revealed an incidence of 15 cases in 26119 (57 per 100,000) overseas
travelers abroad for one month. This rate of approximately 70 per
100,000 person-years is seventy times greater than the incidence
calculated for the U.S. population in the decade 1971-1980(17). No
correlation between infection and any aspect of type, location or duration
of travel was provided, however(29).
A Swedish study demonstrated a hepatitis A attack rate in 1980 of 1.4
per 1000 and 10 per 1000 unprophylaxed travelers to Northern Africa
and Tropical Asia or Africa, respectively(30). The attack rate for
unprophylaxed travelers to southern Europe in 1980 was 0.17 per 1000,

down from 0.33 per 1000 in 1965-1974, a trend attributed by the
authors to improved socioeconomic conditions in the countries of
southern Europe. Another Swedish study, which documents the decline
in attack rate for travel to southern Europe from one in 3000
unprophylaxed travelers in 1970-1972 to one in 20,000 unprophylaxed
travelers in 1982, does not show such a decline in the risk of travel to
Northern Africa, Tropical Africa and Asia. In 1982,

the attack rates were

one in 525, 95 and 144 unprophylaxed travelers to these regions,
respectively(31).
A study of unprophylaxed Danish travelers between the years 19761978 revealed a higher attack rate ( primarily of hepatitis A ) in
individual travelers to endemic regions than in travelers in tourist
groups(32). Attack rates, extrapolated to cases per 100,000 airline
travelers, ranged from 0.3 in individual travelers to northern and central
Europe to 1482 cases per 100,000 airline travelers to Central Africa.
Other areas of risk, in decreasing order, were Central and South America
(740.7), North Africa ( 238.1), Asia (105.2) and the Middle East,
excepting Israel, (86.1)Attack rates were remarkably lower in group
travelers, ranging from 32.5 and 10.3 per 100,000 travelers to North and
Central Africa, respectively, to zero cases for most other regions. A study
by Steffen et. al. (28) in unprophylaxed Swiss travelers, demonstrated an
incidence of 155 cases per 100,000 traveler-months abroad but
identified no subpopulation with specific travel characteristics ( such as
age, destination, purpose, length and type of travel) that had increased or
decreased incidence.

ISIG Prophylaxis
Documentation of Effectiveness
The effectiveness of immune serum immunoglobulin (ISIG) injections
prior to work or travel in developing countries has been demonstrated in
several studies few of which have been strictly controlled and doubleblinded. Often quoted is Woodson's(33) comparison of unprophylaxed
Protestant missionaries with routinely prophylaxed Peace Corps
volunteers, revealing a rate of 3.0 icteric cases and 0.97 icteric or icteric
cases per 100 person-years in the two groups, respectively. A 1969
British study showed a seven month incidence of 0.93 and 8.5 cases per
1000 prophylaxed and unprophylaxed relief workers, respectively(34).
This study also showed that the effectiveness of ISIG waned after 7
months.

Likewise, a truly controlled double-blinded study of American

soldiers in Korea revealed 20 cases of hepatitis A in approximately
30,000 soldiers who had received ISIG within the past six months as
opposed to 43 cases in approximately 20,000 soldiers who had not
received ISIG, but the statistically significant differences between the two
groups disappeared after six months(35). Since double-blind, controlled
clinical trials of the effectiveness of ISIG prophylaxis in travelers to
developing nations have not been performed, current CDC
recommendations are based primarily on these studies in supposedly
similar populations.
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CPC Recommendations
These recommendations call for the intramuscular injection of 0.02
mL/kg ISIG for travelers who will be in developing nations for three
months and 0.06 mL/kg every five months for extended-stay
travelers(48). The classification of countries as "developing" is left ot the
clinician, but extra caution is urged if patients are likely to be traveling in
rural regions or are likely to be living in rustic accomodations.
Aside from limitation of exposure and administration of ISIG, the CDC
also presents the possibility of serologically testing certain people whom
the clinician feels might be immune, in order to avoid unnecessary
injections of ISIG. The CDC handbook does not, however, provide an
indication on what types of people might be tested.
Serological Screening for Immune Status of Certain Subgroups of
the Travel Population as an Alternative to Routine ISIG Prophylaxis
Indeed, although ISIG prophylaxis is effective, there are several
considerations which might make a serological search for immune
individuals a desirable alternative to routine ISIG injections. Although the
safety of intramuscular ISIG is well-documented, there are conditions in
which safety might be of significant concern to the patient, if
quantitatively only of minor concern to the clinician. The cost of ISIG is
currently low enough to make serological screening cost-effective to
patient or provider in only a very restricted set of circumstances.
However, there are situations in which cost of ISIG may become a greater
impetus for serological screening. Finally, there are conditions in which
determination of immunity would be a very convenient alternative to ISIG
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prophylaxis, although it would be difficult to quantify the benefits gained
by serological screening. All of these factors which might make
serological screening for immunity a desirable alternative to routine ISIG
prophylaxis will now be reviewed.
Issues of Safety of ISIG Prophylaxis
Intramuscular administration of ISIG is a safe, as well as effective
procedure, and adverse effects are primarily anecdotal. There have been
reports of non-fatal anaphylaxis but these are extremely rare(45). The
concern over the possible transmission of infectious agents, particularly
human immunodeficiency virus (HIV), has been carefully studied. Several
patients who received ISIG containing antibodies to HIV ( collected
before screening of donors was possible) were found subsequently to have
positive ELISA and Western blot tests, but in all of these patients, the
tests became negative after six months, suggesting that antibody, but not
virus, had been transferred(36,37,38). Indeed, a study of the cold ethanol
fractionation procedure used for ISIG production calculated the
effectiveness of virus removal to be IX10 ^ in vitro infectious units per mL
(IVIU/mL) for all of the steps combined(39). Since 1000 units of
screened blood ( the usual quantity for the preparation of a batch of ISIG)
has been calculated to have a total of 0.13 IVIU/mL, the reduction of viral
titer of 1 O'5 could be expected to produce a very safe product, and no
cases of persistent seroconversion to anti-HIV positivity have been
attributed to ISIG administration(40).
Nevertheless, particularly in those travelers who may require a second
ISIG injection while in a developing country, where blood may not be
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screened, where quality control is limited(41), and where needles may
not be new, prior determination of HAV status may reduce risk by
enabling immune individuals to avoid unnecessary injections.
Issues of Cost of ISIG Prophylaxis
Financial incentives for screening are not compelling but depend on
testing philosophy and differ for patient and provider. For example, the
cost in 1990 of 2 mL of ISIG to the patient at Yale-New Haven Hospital
(YNHH) is $18.00. In comparison, the hospital charges $20.00 for the
anti-HAV IgG ELISA. Hospital policy requires an anti-HAV IgM ELISA for
all positive IgG tests, and charges the patient an additional $20.)) for this
test. Under such circumstances, an immune patient only saves money if
he or she has a 100% chance of immunity and will require more than two
ISIG injections, a condition which would obtain in repeat or extendedstay travelers. If the hospital did not require an anti-HAV IgM test for
obviously healthy pretravel patients with a positive anti-HAV IgG test,
then an immune patient saves money if he or she would have required
more than one ISIG injection.
A provider's considerations are somewhat different, based on costs to
YNHH. One dose of ISIG costs $2.00, the anti-HAV IgG ELISA costs $4.00
and the anti-HAV IgM ELISA costs $10.00. If the provider insists on an
(

IgM test after a positive IgG test, then it saves money if a known immune
individual would have required seven ISIG injections. If the requirement
for the second IgM test is waived, then the provider saves money if an
immune individual would have required two ISIG injections. Clearly, so
long as the present ratio of ISIG administration to HAV test cost remains
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low, cost alone is not a strong impetus for screening except in frequent
travelers. Indeed, cost minimization strategies in the U.S. are currently
not very sensitive to the prevalence of immunity in target populations. It
is conceivable, however, that ISIG could become more expensive if, for
example, supplies became limited. The recent shortage of ISIG due to
large military requirements might provide an added incentive for
screening.
Suitable criteria for screening might also be important when a vaccine
for HAV becomes available, since cost will probably initially be a greater
issue than with ISIG prophylaxis. A recent trial of killed HAV vaccine
produced antibodies at levels higher than those obtained with ISIG, and
which persisted for 24 weeks. Further studies will determine if such a
vaccine will soon be available(43).
Issues of Convenience of ISIG Prophylaxis
Another situation in which it might be convenient to know anti-HAV
antibody status is in those patients who also require revaccination for
measles before travel (ie. those vaccinated before 1980). Because ISIG
interferes with development of active immunity to measles, the vaccine
should not be given for at least six weeks, and preferably for three
months after ISIG injection. Conversely, ISIG should not be given less
than 14 days after a measles vaccine because 7-10 days is required for
immune stimulation. Pretravel preparation might not allow for the
maintenance of such intervals. Thus, identifying HAV immune individuals
among those travelers also needing the measles vaccine might obviate the
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need for untimely ISIG administration which, in turn, would require a
repeat measles vaccine or a check of measles serology(42).
British Studies Assessing Criteria for a Cost-Effective
Approach to Serological Testing
In Great Britain, which has a nationalized health service, the desire of
the health care provider to reduce costs has led to an interest in
determination of screening criteria. According to one British study(44),
ISIG costs

8.00 per administration while a salivary anti-HAV IgG capture

immunoassay costs

4.00. Thus, total cost will be quite sensitive to the

prevalence of immunity in those tested. These investigators found a
prevalence of immunity ranging from 27% in the >20 year old age group
to 45% in the >50 year old age group. Prevalence in those with Asian
surnames was 72% and was 74% in those with a history of jaundice.
Assuming the listed costs of ISIG and the salivaiy test, considering the
average individual lifetime requirement of ISIG to be 1.25 injections, and
taking into account the expected age, racial composition and medical
history of 1000 random subjects ( in whom the total HAV prevalence
would be expected to be 26%), these authors calculated a minimization of
cost if the following groups were tested: 1), frequent or long-stay
travelers >30 years old 2), travelers >60 years old 3), travelers bom in
countries of high HAV prevalence and 4), travelers with a history of
jaundice. Costs could be maintained at current levels while at the same
time minimizing ISIG injections in immune patients by testing patients
with the following criteria: 1) travelers >40 years old, 2), extended - stay
travelers, 3), travelers bom in countries of high HAV prevalence and 4),
travelers with a history of jaundice.
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A more recent study(45) of travelers at an inner-city travel clinic in
London demonstrated an HAV prevalence of 42% in 104 consecutive
travelers tested. Of these immune individuals, 61% had been born or
raised in HAV endemic regions or had a history of jaundice (classified as
major risk factors ) while 27% had a history of drug abuse, living in a
squat or traveling rough, or of living with someone who had had jaundice
( classified as minor risk factors ). Altogether, 48% of those tested who
had minor risk factors were immune, while 100% of those with major
risk factors were immune. However, in this population, 10% of patients
with no risk factor were immune.
Design of This Study to Determine Factors in Past Medical and
Travel History Associated with Hepatitis A Immunity
The purpose of this study was to determine which factors in the past
medical and travel history of U.S. travelers would be associated with
hepatitis A immunity, and to measure the overall prevalence of immunity
in the travel clinic population. The results from this study would assist
clinicians in deciding whom to test for immunity.As the prevalence of
HAV immunity in the travel clinic was determined to be small, it was
decided to do a case-control study(46). Such a study would not allow for a
quantitative assessment of risk factors and would not provide the
information necessary to design a cost-effective strategy for testing.
Nevertheless, it might provide the basis for studies which could obtain
such information if cost or other factors rendered quantitative analysis
more clearly useful.
Given the constraints of the extant database, only certain factors could
be explored. It seemed probable that, as in the study of Parry et. al.(44).
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hepatitis A immunity would be associated with greater age and with a
history of hepatitis. Although surnames cannot be used in the U.S. to
predict with great accuracy one’s origin, birth or upbringing in a
developing country would likely be associated with hepatitis A immunity.
Furthermore, previous travel to developing nations, especially without
evidence of hepatitis A prophylaxis might be associated with hepatitis A
immunity, since such travel would a connote a risk above that of the
general population. Gender, on the other hand, would not be expected to
correlate with hepatitis A immunity. Unfortunately, socioeconomic status
of patients could not be assessed, although travel itself, and attendance at
largely self-pay travel clinics connotes a certain socioeconomic status.
Although these factors are not necessarily independent (eg. older
people have had more time in which they might have traveled abroad),
within the context of the already self-selected population that comes to a
travel clinic, they may provide the clinician with extra impetus to
immunologically screen. Likewise, certain aspects of patients’ travel
intentions might prove reflective of factors in their past which are
predictive of hepatitis A immunity. Thus, intended destination, purpose
and length of travel were recorded.
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Methods

Patients who attended the Yale Tropical Medicine and Traveler’s
Clinic(YTC) or the Yale University Health Services travel clinic(YHP)
between January 1987 and September 1990 for pretravel counsel and
immunizations were routinely tested for anti-HAV IgG antibodies in their
serum. One of the travel clinic physicians!J.P.) claimed to have tested a
preponderance of older patients while another physician(M.B.) reported
testing all travel clinic patients coming for pretravel evaluation. Potential
distinguishing factors in the subjects tested by two other travel clinic
physicians are not known. The serological test used was the HAVAB
Enzyme Immunoassay Kit produced by Abbott Laboratories. Patients were
also questioned about various aspects of their past medical and travel
history and responses were generally recorded in a standardized form. If
time permitted, patients would return to the clinic just prior to travel
for ISIG administration if they were found not to be immune, otherwise
they would receive ISIG without waiting for the results of serological
testing.
Beginning in Spring, 1990, logbooks were reviewed manually or by
computer search to find the unit numbers or the names of immune and
non-immune patients. Identification of the birthdates of nearly all of
those tested provided data on HAV prevalence in different age-groups.
The charts of patients at the Yale Travel Clinic were checked and the
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data concerning their past medical and travel history were collected.
Specifically, age, gender, birthplace, current travel plans at time of visit,
reason for travel, length of intended stay, and past history of hepatitis and
previous travel were reviewed. Patients whose charts were incomplete
were contacted by mail and invited to fill out a written questionnaire or
provide responses over the telephone. Because the charts of YHP travel
clinic patients were unavailable, mailed questionnaires were used to
obtain information on their medical and travel history.
Although contact with all non-immune patients was not attempted,
subjects were chosen randomly to provide a 2:1 ratio of controls to cases.
The names of several non-immune subjects listed on either side of those
of immune subjects in the logbooks or computer printouts were selected.
Because there was a greater number of non-immune subjects available for
study, non-immune subjects with incomplete charts were not pursued,
instead, the completed charts of other non-immune subjects would be
selected. Collection and treatment of data proceeded according to the
regulations of Protocol #5612 of the Human Investigation Committee of
Yale University School of Medicine and the of the Yale University Health
Services.
Results were tallied and responses for various aspects of medical and
travel history in immune and non-immune subjects were compared.
Differences in the percentages of immune cases and non-immune
controls with certain factors were tested for statistical significance by
computing a chi-squared value and interpreting this with one degree of
freedom to find the two-tailed p value. If the number of subjects included
in a test for statistical significance was less than 150 or if the p value was
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greater than 0.005, the Yates continuity correction was used. Odds ratios
and the associated 95% confidence intervals were also calculated. The
Mantel-Haenzel tests for confounding and effect modification were
performed where possible.
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Results
Results of Age-Prevalence Study
HAV-Immune subjects/Total subjects in group(%)
Age-group(years)
10-19

20-29

30-39

40-49

50-59

60-69

>70

Total

0/1(0)

5/73(7)

10/43(23)

4/24(17)

1/9(11)

7/18(39)

7/8(88)

43/183(19)

14/79(18)

14/82(17)

14/53(26) 7/24(29)

71(493(14)

0-9
YHP 0/7(0)
YTC 0/4(0)

0/20(0) 9/112(8) 13(119)11

Tot. 0/11(0)

0/21(0)14/185(8)23/162(14) 18/103(17)15/91(16)

21/71(30)14/32(44)105/676(16)

(YHP signifies Yale University Health Services and YTC signifies Yale Tropical Medicine and
International Traveler's Clinic)

HAV-Immune Subjects/Total Subjects in Group(%)
Age-Group(yrs.)
>10
>20
>30
>40
>50
>60

YHP

YTC

Total

34/176(19)
34/175(19)
29/102(28)
19/59(32)
15/35(43)
14/26(54)

71/489(15)
71/469(15)
62/357(17)
49/238(21)
35/159(22)
21/77(27)

105/665(16)
105/644(16)
91/459(20)
68/297(23)
50/194(26)
35/103(34)

Results of Case-Control Study
DESCRIPTION OF SUBJECTS

Immune

Non-immune

62

121

53(18-81)

38(17-71)

Males(%)

27(44)

63(52)

Females(%)

35(56)

58(48)

Total
Mean Age(range)
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AGE
Subjects(% cf subjects in row)
Age-Group(years)

0-19

20-29

30-39

40-49

50-59

60-69

>70

Total

Immune

1(2)

3(5)

9(15)

12(19)

12(19)

18(29)

7(11)

62

Non-immune

2(2)

35(29)

34(28)

21(17)

18(15)

10(8)

10)

121

Total

3(2)

38(21)

43(23)

33(18)

30(16)

28(15)

8(4)

183

GENDER
Subjects(% of subjects in that row)
Male

Female

Total

Immune

27(44)

35(56)

62

Non-immune

63(52)

58(48)

121

Total

90(49)

93(51)

183

p>0.25 NS

HISTORY OF HEPATITIS
Subjects(% of subjects in that row)

Immune
Non-immune
Total

History of Hepatitis

No History of Hepatitis

Total

20(32)

42(68)

62

2(2)

119(98)

121

22(12)

161(88)

183
pc.001
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PLACE OF BIRTH
Subjects (% of subjects in that row)
Bom in U.S.

Not Bom in U.S.

Total

Immune

40(65)

22(35)

62

Non-immune

107(88)

14(12)

121

Total

147(80)

36(20)

183

Breakdown of Place of Birth—Immune Subjects
Region or Country
Ghana
Bangladesh
India
Egypt
Israel
Vietnam
Thailand
Argentina
Chile
W. Europe

Number of Subjects
2

2

2
1
1
1
1
1
1
9 (Germany-1,Italy-3, Britain-2,
Austria-1, France-1)
Not U.S. (not otherwise specified) 1

Breakdown of place of birth--Non-immune subjects
Region or Country
Libya
Israel
Curacao
Japan
W. Europe

Number of Subjects
1
1
1
2
2
(Netherlands-1,
Norway-1)
1
Canada
Not U.S. (Not otherwise specified)
6
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PROFILE OF DESTINATIONS OF TRAVELERS

Immune Subjects:
Number of responses(% of subjects). Percentages will sum to greater than
100% due to multiple responses from some subjects.
South/Central America
11(18)

N. Africa Other Africa S.E. Asia
7(11)
30(48)
10(16)

Country or Region

Other
11(18)

Number of Subjects

Kenya
Tanzania
India
Egypt
Ghana
Mexico
Thailand
Peru
China
Senegambia
Nepal
Zimbabwe
Honduras

8
6
5
4
4
4
3
3
2
2
2
2
1

Mentioned once:
Philippines, Taiwan, Singapore, New Guinea, HongKong, Bali, S.E. Asia,
Bangladesh, Pakistan, Mali, Cameroon, Morocco, Mauritania, N.W. Africa,
Burundi, Mozambique, Liberia, Tunisia, S. Africa, Central African
Republic, Brazil, Uruguay
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Non-immune Subjects
Number of Responses(% of subjects). Percentages will sum to greater
than 100% due to multiple responses from some subjects.
South/Central America N. Africa Other Africa S.E. Asia
44(36)
6(5)
54(45)
16(13)

Region or Country
India
Kenya
Nepal
Brazil
Tanzania
Galapagos
Zimbabwe
Thailand
Peru
Haiti
South Africa
Egypt
Singapore
Liberia
Belize
Guatemala
Nicaragua
Costa Rica
Sri Lanka
Dominican Republic
Japan
Morocco
Senegal
Togo
Venezuala
Central Asia

Other Asia
39(32)

Number of Subjects
20
19
11
10
10
6
5
5
5
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2

Mentioned once:
Mali, Ivory Coast, Ethiopia, Zaire, Cameroon, Burundi, Zambia, N.W.
Africa, Nigeria, Uganda, Botswana, Mauritania, Guyana, Ecuador, Mexico,
Honduras, Argentina, S. Asia, Malaysia, Philippines, Hong Kong, Pakistan,
Vietnam, Cambodia, Hawaii, Bhutan, Saudi Arabia, Israel
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COMPARISON OF PROJECTED LENGTH OF TRAVEL
Subjects(% of total of that row)
less than or equal to 3 wks.

>3wks.<lyr.

>iyr.

Not Mentioned

Total

Immune

37(60)

17(27)

3(5)

5(8)

62

Non-immune

66(55)

50(41)

5(4)

0(0)

121

Comparison of Purpose of Travel
Responses(% of subjects in that group)
(Percentages sum to greater than 100% because of multiple responses from some subjects)
Business Volunteer Wk. Study Tourist Visit Relative

Field Wk. Not Mentioned

Sub.

Immune 8(13)

9(15)

1(2)

32(52)

6(10)

3(5)

5(8)

62

Nonimmune 14(11)

23(19)

10(8)

70(57)

3(2)

2(2)

0(0)

121

Total

32(17)

11(6)

102(55)

9(5)

5(3)

5(3)

183

22(12)

Continent of previous developing nation travel
Responses(% of subjects in that row)
(% may add up to greater than 100% due to multiple responses from some subjects)
Asia

South/Central America Africa

Other

None

Immune

25(40)

17(27)

23(37)

2(3)

8(13)

Non-immune

47(39)

31(26)

29(24)

1(1)

46(38)

Number of subjects with history of previous developing nation travel
with history of associated immunization (not necessarily ISIG)
Subjects(% of subjects with previous developing nation travel)
Some evidence of previous
pretravel care

No evidence, or denial of '
previous pretravel care

Total

Immune

27(50)

27(50)

54

Non-immune

24(32)

51(68)

75

p>.05 NS

Evidence of previous pre-travel care included recollection of previous
pre-travel immunizations or records of previous pre-travel visits or
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immunizations in medical charts. In the other category were placed
subjects who denied previous pre-travel medical care or whose medical
charts contained no evidence of previous pre-travel visits. Patients who
had had pre-travel visits for some but not all trips to developing nations
were entered as having evidence of previous pre-travel medical care.

Statistical Analysis
I. Age-Prevalence Study in YHP and YTC Populations
The overall prevalence of HAV immunity in the YHP and YTC
populations was 19% and 14%, respectively. To test if this difference
between the two populations was statistically significant, a 2x2 table
was constructed, with clinic source as the "risk factor" and the
number of subjects in each category entered into the appropriate cells.
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At one degree of freedom (df), p(two-tailed)>0.10, signifying that
there is a greater than 10% probability that this difference arose by
chance. (All p values subsequently presented will be two-tailed and
interpreted at 1 df).
The differences in prevalences between similar age-groups in the
two populations were also checked separately for statistical
significance.
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II. Case-Control Study
A. Analysis of the different age-groups amongst the cases and controls.
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The odds ratio (or, the ratio of the likelihood that immune subjects
will have exposure to the "risk factor" to the likelihood that nonimmune subjects will have such exposure) is determined by the
following formula:
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The 95% Confidence Interval (95% Cl) of an odds ratio is calculated
according to the formula:
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The association of increased age with immunity may be due to the
confounding effects of the increased opportunity of older people
already to have had previous travel to developing nations and to already
have had hepatitis. A confounding factor must be independently
associated with exposure (here, increased age), outcome (immunity),
and not lie on the causal pathway from exposure to outcome. One way
to control for confounding is by stratification of the odds ratios by
previous travel and by previous hepatitis status, and to calculate the
Mantel-Haenzel odds ratio. The Mantel-Haenzel(MH) analysis requires
categorical variables and so age-groups have been stratified into >40
year-olds and <40 year olds for this and all subsequent MH analyses.
Assessing for the effect of previous travel:
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These results will be discussed in the Conclusions section. The
possible confounding effects of hepatitis in older subjects cannot be
assessed by the MH procedure because one of the cells has a value of
zero. However, one can check if age and hepatitis could be associated
by comparing the average age of immune subjects with a hepatitis
history with the average age of those without such a history. If the
former group were much younger than the latter, then it would appear
that hepatitis and increased age were not associated. Since the
approximate age of both groups is approximately 53 years old, one
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cannot rule out the possibility that increased age and hepatitis history
are associated and therefore, may be confounding each other's
association with HAV immunity.
B. Gender
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C. Place of Birth
An attempt is made in the Conclusions section to distinguish foreignbom (developed and developing countries) and U.S. bom populations
on the basis of average age. The two-sample t-test was used to
determine statistical significance of the differences between two
means. Thus:
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An MH analysis was used to assess the confounding effects of previous
travel to developing nations and of a hepatitis history in the association
of immunity and foreign birth. (N.B. Small cell numbers may lessen the
validity of some of these analyses). Effect of previous travel:
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As the OR^ is approaching unity, a second test for statisitical
significance must be performed using a weighted Mantel-Haenzel chi
square calculated according to the formula:
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For a hepatitis history, there are several possible confounding factors.
1. Patients with a history of hepatitis may be older and for this reason
may be more likely to be found amongst immune patients.
2. Patients with a history of hepatitis may be more likely to have a
history of previous travel to developing nations and for this reason may
be more likely to be found amongst immune patients.
3. Patients with a history of hepatitis may be more likely to have been
born outside of the U.S. and for this reason may be more likely to be
found amongst immune patients.
The first two of these possibilities are not amenable to MH analysis
because of zero subjects in some cells. However, it has been shown in
the analysis of age that hepatitis history and age cannot be shown not
to be associated. Applying MH analysis to the third possibility:
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Assessment of the possible confounding effect of hepatitis could not be
done because of zero subjects in some cells. Assessment of
confounding effect of greater age:
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F. Expected Destinations of travelers not assessed statistically.
G. Expected Length of Travel (disregarding subjects with unspecified
lengths of travel):
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H. Purpose of Travel not assessed statistically.
I. Subjects with a history of previous travel to developing nations who
give a history of associated immunizations:
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Discussion
Prevalence of HAV immunity was 19% and 14% in the YHP and YTC
populations, respectively, with an increasing prevalence with
increasing age. In the case-control aspect of the study, immune
individuals were found more likely than non-immune individuals to be
older, to have traveled previously, to have been bom outside of the U.S.
or to have a history of hepatitis. Mantel-Haenzel (MH) analysis was
performed where possible to determine the importance of
confounding and effect-modification in the associations between these
factors and HAV immunity. No other factors were found to be
associated with HAV immunity. Various biases were assessed and
considered to be of limited significance in this study.
General Prevalence
As the differences between the YHP and YTC populations were
determined not to be statistically significant (p>0.05), it was decided
to pool the results from the two groups, although incurring a Type II
error in so doing was certainly a possibility .The prevalence of HAV
immunity in the combined groups was 15.5%, which is lower than the
26% and 42% reported for two British travel clinic
populations(44,45). The prevalence was also lower than that reported
in an American middle-class population in 1976(15,16).

Because ours

was a case-control study, however, the proportions of other subgroups
in the two populations (such as individuals bom outside the host
country or individuals with a history of hepatitis) could not be
compared. Likewise, a comparison of our group with that of Szmuness
et. al.(15) is not possible. Nevertheless, one could speculate that our
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group came from a higher socioeconomic background than did those
from the previous American study and from the British inner-city
study(45).(Indeed, it is unlikely that 10% of our travel population had
a history of drug abuse, living in a squat or traveling rough, as was the
case in that British study) .Another possible explanation for a lower
prevalence of HAV immunity in our study could be a reduced
prevalence in the population as a whole as compared with those in
Britain or those in the U.S. in the 1970's. Finally, it should be
remarked that in the study of Parry et. al.(44), a conscious effort was
made to test a population likely to have a higher prevalence of HAV
immunity, though the degree to which this overestimated the
prevalence of the population as a whole is not clear. It is interesting to
note that very little work on the prevalence of HAV immunity in the
U.S. has been done since the 1970's, although it is not certain that
revelation of any changes would be very useful since the incidence of
hepatitis A is currently very low and since outbreaks usually have wellrecognized sources.
Age Factor and Hepatitis A Immunity
The increasing prevalence with increasing age was expected. Older
patients have had more time in which to be exposed to HAV and to
develop lifelong immunity. Furthermore, seroepidemiologic data from
the developed nations suggest that it is within the past 50-75 years
that hygienic standards progressed to a point capable of reducing
incidence of hepatitis A, and so, older patients have lived in time
periods when incidence was higher than it is now(22,23).
An analysis of the age profiles of the case-control study groups
reflects the increased prevalence with increased age by demonstrating
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a greater likelihood that immune individuals will be older than a
certain age than their non-immune controls will be. The only age cut¬
off where such a likelihood is not statistically significant is 20 years
old. The odds ratios do not follow an explicable pattern but statistical
significance is greatest for the age cut-off of 60 years where it is seen
that immune individuals are 6.8 times more likely to be over 60 years
old than are their non-immune counterparts.
The possible confounding effect of previous travel to developing
nations and of a hepatitis history was assessed because older patients
may have had more time to experience either of these potential
factors than younger patients will have had, and these factors may be
independently associated with immunity. Stratifying the >40 and <40
year-old age-groups by presence or absence of previous travel did not
reduce the MH odds ratio, and so the greater odds of older people
being found among immune individuals is not due to the greater
possibility that they will have traveled previously. On the other hand,
there is striking effect modification, wherein it is seen that immune
subjects with a history of previous travel have a less increased
likelihood(OR=4.5) to be found to be older than immune subjects
without such a history(OR=l 1.9), suggesting that age and previous
travel are independently associated with immunity. (Ie. if one factor
accounts for a subject's immunity, then the other does not).
Alternatively, if one considers odds ratios to be equivalent to risk
ratios (which can be done for low-prevalence outcomes), the presence
of previous travel reduces the relative risk of older age "causing"
immunity. What this means biologically is not clear, however, the
presence of effect modification
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informs the clinician that increased

age will be a more important predictive factor for immunity in patients
without a history of previous travel to developing nations than in those
with such a history. The possibility that an older person will have had
more time to contract hepatitis and that this accounts for the
increased odds of finding older people among immunes could not be
checked by the MH procedure, and calculation of average ages
demonstrated that an association of age and hepatitis cannot be ruled
out. ( Note that such an association between age and symptomatic
hepatitis presumably accounts for only part of the increased
prevalence of immunity in older people, as one expects many of these
older people to have developed immunity when hepatitis A was an
endemic disease and therefore, more likely to express itself in
asymptomatic form. Indeed, to be a true confounder, cases of
symptomatic hepatitis cannot be a result of increased age).
Gender Factor and Hepatitis A Immunity
Gender was shown not to bear a statistically significant relationship
to immunity. Although immune individuals were only 0.71 times as
likely to be males as were their non-immune counterparts, the chi
square value demonstrated that there was a greater than 25%
probability that this discrepancy had occurred by chance.
Furthermore, the 95% Cl of the odds ratio (0.38 to 1.32) includes 1.0,
which implies no added or reduced likelihood of immune individuals
being male. It was not expected that immunity would be associated
with one gender or another, since hepatitis A has no known sex
predilection.
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Place of Birth and Hepatitis A Immunity
Conversely, immune individuals were found to have a statistically
significant 4.2 times greater probability of being born outside the U.S.
than were non-immune individuals. This would imply that individuals
bom outside of the U.S. have a higher prevalence of immunity to
hepatitis A, as was also suggested by the data of Szmuness et. al.(15).
The mean ages of U.S. bom and foreign-bom immune subjects were
57.3 and 45.5, respectively(p<.005) which suggests that age and
foreign birth are independently associated with immunity. (Such a
discrepancy in mean ages(38.4 years) between foreign and U.S.-bom
non-immune subjects did not exist, further supporting the
independence of age and place of birth in determining immunity). An
increased prevalence might be expected in those born in developing
countries as well as in older patients bom in countries which had a
higher incidence than the U.S. years ago, but which may be considered
developed countries now and which have a low incidence currently.
Approximately one-half of the foreign-born individuals were from the
developing countries while the rest were from western Europe. Their
mean ages were 38.5 and 55.6 years, respectively,(p<.001), which
would seem to support such a distinction. (On the other hand, a
discrepancy also existed between the mean ages of foreign-bom nonimmune subjects from developing and developed countries(27 and 36
years, respectively),although statistical significance was much
less(p<.05) and many foreign-bom subjects had not provided a country
of birth).
The possibility that foreign-bom individuals were more likely to have
previously traveled to developing nations, or to have had hepatitis, and
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that either of these possibilities may have accounted for the increased
odds of finding foreign-bom subjects among immunes was subjected to
MH analysis. Indeed, because more foreign-bom individuals were
likely to have traveled previously, the adjusted OR^of 3.6 was lower
than the crude OR of 4.2. Nevertheless, one notes an effectmodification wherein immune subjects with a history of previous travel
have a less-increased likelihood of being found to be foreignbom(OR=3.4)

than those without previous travel(OR=4.8), suggesting

that although foreign-bom individuals are more likely to have had
foreign travel, this does not account for their immunity. A hepatitis
history is found not to be a confounding factor(OR^H=4.2). Moreover,
the effect modification shows that a hepatitis history and foreign birth
are unlikely both to account for one's immunity. Again, considering
odds ratios to be equivalent to risk ratios, one could conclude that
foreign birth is a more useful predictive factor for immunity in those
patients without a history of hepatitis or of previous developing nation
travel than in those with such a history.
Hepatitis History and Hepatitis A Immunity
Immune individuals had 28.3 greater odds of having a history of
hepatitis than did non-immune individuals. It would be expected that a
past episode of hepatitis would be correlated with HAV immunity even
if, as noted in previous studies(15,16), only 3-5% of HAV immune
individuals will give a history of hepatitis. This study suggests that 32%
of immune individuals can give such a history. This may signify that
travel patients develop hepatitis A in a context in which it is more
likely to be symptomatic or diagnosed, a possibility that would seem
consistent with the expected higher socioeconomic status of travelers.
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On the other hand, some of the patients with hepatitis were young and
were born outside of the U.S. and so may have contracted hepatitis A
in an endemic region.
It has been shown that a history of hepatitis and of increased age
may be associated with each other, although the nature of this
association is not demonstrable with these data. The possible
association of previous travel and hepatitis history could not be
assessed because of cells with zero subjects. The possible confounding
effect of foreign-birth(associated with, but not causing a hepatitis
history, and associated with immunity) was shown to be significant, as
the ORof 19.6 is markedly reduced from the crude OR of 28.3.
Nevertheless, a history of hepatitis is still a very important factor
associated with immunity and could be considered to be highly
predictive of immunity, particularly in U.S. bom patients.
Previous Travel and Hepatitis A Immunity
Previous travel to developing countries was expected to have some
correlation with immunity.Even prophylaxed travelers from the U.S.
have, according to the data of Woodson(33) and Conrad and
Lemon(35), a 7-100-fold greater incidence of hepatitis A than
individuals in the U.S.(17). The incidence is even greater for
unprophylaxed travelers. Two of the twenty immune individuals with a
history of hepatitis in this study had developed hepatitis during
previous travel, although one of these cases occurred in France from
eating raw seafood. Since most cases of travel hepatitis would occur in
adults and thus, be symptomatic, it is surprising that despite the large
percentage of immune travelers who had traveled to developing
countries, only one of them could attribute immunity to that factor.
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Nevertheless, immune subjects had a 4.1 times greater probability of
previous travel to developing nations than did non-immune subjects.
An MH analysis for confounding of the association of immunity and
previous travel by hepatitis history was not done due to zero values in
some cells. One might doubt the value of such an analysis anyways,
because one would expect that most immunity secondary to previous
travel would arise from symptomatic cases of hepatitis A (since most
travelers are adults). If this were the case, a hepatitis history would lie
along the causal path from exposure(travel) to outcome (immunity)
and thus not fulfill the criteria for a confounding factor. Greater age is
shown not to confound the association of previous travel with
immunity(OR^ =4.0

ORcrj=4.1), although a history of previous travel

to developing nations is of greater predictive value in younger
patients(OR=8.3) than in older patients. Foreign birth does confound,
to some extent, the association of immunity with previous travel (OR
=3.6) although the MH chi square and the 95% Cl of OR^ suggests
that the association is still statistically significant. One notes some
effect modification; thus, previous travel is of greater predictive value
for immunity in U.S. bom individuals than it is in foreign-bom
individuals.
Previous Pretravel Care and Hepatitis A Immunity
An attempt to find a correlation between a lack of previous pretravel care and immunity failed to achieve statisitical significance.
Since very few charts and very few recollections provided specific
information on presence or absence of ISIG prophylaxis before some
or all trips abroad, presumptive evidence had to be considered. For
example, immunizations against yellow fever and cholera, or previous
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use of antimalarials was considered as evidence of pre-travel medical
care during which ISIG may have been administered. The absence of
any such information, which was taken as evidence of no pre-travel
medical care, may have been due instead, simply to omission of such
data. Thus, the presumptive nature of the data may very well account
for the inconclusiveness of this part of the study.
Destinations of Travel in Travel Clinic Patients
The destinations of immune and non-immune individuals were not
subjected to statistical analysis because no trend was readily apparent
in the destinations of the two groups. Furthermore, it would have been
difficult to explain how any trend would reflect a greater probability of
being immune. The destinations, however, represent a fair distribution
in the areas shown to be of increased hepatitis A risk for travelers ie..
Tropical Africa, South and Central America, Asia and North Africa. The
data on attack rates do not enable one to make very refined estimates
of risk for individual travelers. For example, attack rates are probably
lower in the more developed areas of Southeast Asia such as Thailand,
Hong Kong and Taiwan than they are in China, but the attack rate is
only estimable for travel to Asia as a whole.
Purpose of Travel in Travel Clinic Patients
Likewise, purpose of travel probably influences one's risk for
contracting hepatitis A , but data are not available for quantifying how
it might do so. Intuitively, one would expect that business and study
which took place in urban centers would pose the lowest risk while
field research and volunteer work might pose the greatest risk.
Traveling as a tourist probably presents a wide range of risks; whereas
the Steffen study(28) did not show that the "roughness" of travel
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affected incidence, the Danish study(32) demonstrated much higher
attack rates in individual as opposed to group travelers. Five out of six
immune individulals visiting relatives had been bom in the developing
country they were visiting, whereas none of the non-immune travelers
visiting relatives were bom outside of the U.S. This suggests that most
travelers visiting relatives in a developing nation in which they
themselves were bom would probably already be immune. Presumably,
visits to relatives could pose substantial risks to non-immune subjects
since such visits might involve significant personal contact and living
in households with very young, untoilet-trained children.
Assessment of Biases
Although nearly all patients entering the travel clinic were tested,
the study was potentially subject to several types of biases.
Informational bias is possible because conceivably, patients more likely
to be immune may have experienced differential recall of past history,
as they may have had a more sophisiticated knowledge of travelrelated diseases since they were older, more likely to have been
foreign-born and were more likely to have traveled previously.
Observer bias was avoided either by questioning patients before test
results were known, or by asking the same specific questions of both
immune and non-immune individuals. Confounding bias results from
the potential associations between the factors associated with
immunity independent of their association with immunity. Mantel
Haenzel (MH) analysis where possible and appropriate demonstrates
some cases of confounding but in no cases did confounding remove all
statistical significance from given odds ratios. Furthermore, the
revelation of effect modification by subgroup analysis demonstrated

54

that some factors are (if odds ratios are interpreted as risk ratios)
more predictive of immunity in the absence of other factors. This is in
contrast to synergism, which might have occurred, if having multiple
"risk factors" increased a given subject's chance of being immune.
The pervasive problem of selection bias is only somewhat
problematic. Patients at travel clinics are clearly a self-selected
population amongst travelers. Nevertheless, this study only concerns
itself with patients who, for various reasons, refer themselves to travel
clinics before travel to developing nations. The degree of selection bias
introduced by the preponderance of older patients in the subjects
tested by physician J.P. is not clear. Nevertheless, the effect of such a
bias would be a potential underestimation of the association of
increased age with immunity, an association already demonstrated in
the age-prevalence portion of the study. The difference in follow-up of
immune and non-immune patients was felt not to introduce a
significant amount of selection bias since there were no apparent
differences between non-immune individuals with complete charts
and those without complete charts.

55

Summary
This study demonstrated a directly age-related increase in the
prevalence of hepatitis A immunity in two university-affiliated travel
clinic populations, with an overall prevalence of 15.5%. In the casecontrol aspect of the study, it was found that immune individuals were
older, and were more likely to have been bom outside of the U.S., to
have a history of hepatitis and to have traveled to developing nations
than were their non-immune controls. Conversely, gender, destination
of travel, purpose of travel and evidence of previous pretravel medical
care could not be shown to bear any relationship with HAV immunity.
Confounding and selection biases were found not to significantly
affect the results of this study. On the other hand, MH analyses
revealed several cases of effect-modification. Thus, increased age was
shown to have a stronger association with HAV immunity in the
absence of a concurrent history of previous developing nation travel.
Likewise, foreign birth was associated more strongly with HAV
, immunity in younger patients than in older patients, and in patients
without a history of hepatitis or of previous travel to developing
nations. Finally, a history of hepatitis was found to have a stronger
association with HAV immunity in U.S.-bom individuals than in
foreign-bom individuals.
As has been discussed, travelers to developing nations are at risk for
developing hepatitis A, which can be a serious disease. Classification of
patterns of infection and avoidance of vehicles of transmission are not
considered to be reliable means of control. The CDC, therefore.
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recommends prophylaxis with ISIG. Although this procedure is safe,
effective and relatively cheap, it must be repeated every four to six
months for repeat or extended-stay travelers. Furthermore, conditions
exist in which the safety, cost and convenience may be of concern to
travelers, if not always to clinicians. Thus, serological screening for
pre-existing hepatitis A immunity may be an alternative to routine ISIG
prophylaxis, since immune individuals do not need ISIG.
This study has identified factors that may be associated with
hepatitis A immunity in patients at U.S. travel clinics in general. The
clinician can determine if a patient has any of these factors in a
routine medical interview. Patients with one or some of these factors
can be counselled on the possibility of serological determination of
immune status instead of routine ISIG prophylaxis before travel to
developing nations. Although this study does not provide the data
necessary to design a cost-effective strategy for screening, it does,
within the context of clinical judgment, allow the clinician to make an
informed choice about whom to test. The patient who is found to be
immune can thereby avoid unnecessary injections which are painful,
and which may be associated with issues regarding safety, cost and
convenience, which, though difficult to quantify, may be of
considerable concern to the patient.
Furthermore, this study furnishes the groundwork for future
research which could provide data necessary for the design of a costeffective screening program. Populations with the factors identified in
this study could be tested, to determine the prevalence of hepatitis A
immunity in these groups, as compared with the prevalence in the
general travel clinic population. Combined with potentially changing
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concerns of cost and safety, these data would allow for the design of a
cost-effective screening program.
In the interim, however, it is hoped that this study will enable some
patients to avoid unnecessary injections of ISIG. Although the benefits
derived thereby have been difficult to quantify, the opportunity to
spare patients unnecessary pain, concern and inconvenience is a
reasonable accomplishment of this clinical research project.
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